Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis

Huilin Tang, Wenting Wu, Shuangshuang Fu, Suodi Zhai, Yiqing Song, Jiali Han

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. Objective We quantify the association between use of PDE5 inhibitors and melanoma. Methods We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that were conducted up to July 13, 2016, and evaluated the association between PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate the adjusted odds ratio (OR) with the 95% confidence interval (CI). Results Five observational studies were included. Compared with PDE5 inhibitor nonuse, PDE5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. Limitations We included only observational studies, which had some heterogeneities and inconsistent controlling for potential confounders. Conclusions Use of PDE5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

Original languageEnglish (US)
Pages (from-to)480-488.e9
JournalJournal of the American Academy of Dermatology
Volume77
Issue number3
DOIs
StatePublished - Sep 1 2017

Fingerprint

Phosphodiesterase 5 Inhibitors
Meta-Analysis
Melanoma
Basal Cell Carcinoma
Odds Ratio
Confidence Intervals
Observational Studies
Squamous Cell Carcinoma
Skin Neoplasms
PubMed
Prospective Studies

Keywords

  • basal cell carcinoma
  • melanoma
  • meta-analysis
  • PDE5 inhibitor
  • squamous cell carcinoma

ASJC Scopus subject areas

  • Dermatology

Cite this

Phosphodiesterase type 5 inhibitors and risk of melanoma : A meta-analysis. / Tang, Huilin; Wu, Wenting; Fu, Shuangshuang; Zhai, Suodi; Song, Yiqing; Han, Jiali.

In: Journal of the American Academy of Dermatology, Vol. 77, No. 3, 01.09.2017, p. 480-488.e9.

Research output: Contribution to journalArticle

Tang, Huilin ; Wu, Wenting ; Fu, Shuangshuang ; Zhai, Suodi ; Song, Yiqing ; Han, Jiali. / Phosphodiesterase type 5 inhibitors and risk of melanoma : A meta-analysis. In: Journal of the American Academy of Dermatology. 2017 ; Vol. 77, No. 3. pp. 480-488.e9.
@article{eb817adb88084de0acf7db19b45eac91,
title = "Phosphodiesterase type 5 inhibitors and risk of melanoma: A meta-analysis",
abstract = "Background The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. Objective We quantify the association between use of PDE5 inhibitors and melanoma. Methods We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that were conducted up to July 13, 2016, and evaluated the association between PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate the adjusted odds ratio (OR) with the 95{\%} confidence interval (CI). Results Five observational studies were included. Compared with PDE5 inhibitor nonuse, PDE5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95{\%} CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95{\%} CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. Limitations We included only observational studies, which had some heterogeneities and inconsistent controlling for potential confounders. Conclusions Use of PDE5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.",
keywords = "basal cell carcinoma, melanoma, meta-analysis, PDE5 inhibitor, squamous cell carcinoma",
author = "Huilin Tang and Wenting Wu and Shuangshuang Fu and Suodi Zhai and Yiqing Song and Jiali Han",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.jaad.2017.04.1129",
language = "English (US)",
volume = "77",
pages = "480--488.e9",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Phosphodiesterase type 5 inhibitors and risk of melanoma

T2 - A meta-analysis

AU - Tang, Huilin

AU - Wu, Wenting

AU - Fu, Shuangshuang

AU - Zhai, Suodi

AU - Song, Yiqing

AU - Han, Jiali

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. Objective We quantify the association between use of PDE5 inhibitors and melanoma. Methods We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that were conducted up to July 13, 2016, and evaluated the association between PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate the adjusted odds ratio (OR) with the 95% confidence interval (CI). Results Five observational studies were included. Compared with PDE5 inhibitor nonuse, PDE5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. Limitations We included only observational studies, which had some heterogeneities and inconsistent controlling for potential confounders. Conclusions Use of PDE5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

AB - Background The association between phosphodiesterase type 5 (PDE5) inhibitors and melanoma risk is controversial. Objective We quantify the association between use of PDE5 inhibitors and melanoma. Methods We systematically searched PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, and ClinicalTrials.gov for studies that were conducted up to July 13, 2016, and evaluated the association between PDE5 inhibitors and skin cancer. Random effects meta-analyses were used to calculate the adjusted odds ratio (OR) with the 95% confidence interval (CI). Results Five observational studies were included. Compared with PDE5 inhibitor nonuse, PDE5 inhibitor use was slightly but significantly associated with an increased risk for development of melanoma (OR, 1.12; 95% CI, 1.03-1.21) and basal cell carcinoma (OR, 1.14; 95% CI, 1.09-1.19) but not squamous cell carcinoma. For melanoma risk, none of the prespecified factors (dose of PDE5 inhibitor, study design, and study region) significantly affected the results (P > .05). Our sensitivity analysis confirmed the stability of the results. Limitations We included only observational studies, which had some heterogeneities and inconsistent controlling for potential confounders. Conclusions Use of PDE5 inhibitors may be associated with a slightly increased risk for development of melanoma and basal cell carcinoma but not squamous cell carcinoma. However, further large well-conducted prospective studies with adequate adjustment for potential confounders are required for confirmation.

KW - basal cell carcinoma

KW - melanoma

KW - meta-analysis

KW - PDE5 inhibitor

KW - squamous cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85024377415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024377415&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2017.04.1129

DO - 10.1016/j.jaad.2017.04.1129

M3 - Article

C2 - 28728871

AN - SCOPUS:85024377415

VL - 77

SP - 480-488.e9

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -